Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The company is conducting the REVEAL and ASPIRE clinical trials in the United States and Canada to evaluate the safety and efficacy of TSHA-102 in pediatric and adult patients. TSHA-102 has received orphan drug designation, rare pediatric disease designation, Fast Track Designation, Regenerative Medicine Advanced Therapy designation, and Breakthrough Therapy designation from the U.S. Food and Drug Administration, as well as orphan drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the U.K. Medicines and Healthcare Products Regulatory Agency. The company’s pipeline includes additional programs targeting monogenic diseases of the central nervous system in both rare and large patient populations.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage tayshagtx.com
Sector Healthcare IR page ir.tayshagtx.com
Tags
gene therapy, aav9, rett syndrome, neurodevelopmental disorders, monogenic diseases, central nervous system, intrathecal delivery, rare diseases, clinical-stage, biologics, TSHA-102, REVEAL, ASPIRE
Press page —

Metrics

Valuation  
Market cap $ 1.587B
Market cap (USD) $ 1.587B
P/E -11.33
PEG —
P/BV 4.45
P/S 162.39
P/OCF -11.26
P/FCF -16.91
Dividend yield —
Turnover / mcap —
Returns  
ROE -68.5%
ROI -36.7%
ROIC -27.9%
Profit margin -1,115.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 13.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score -87.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue 9.773M 8.333M 15.451M 2.502M — —
Net profit -108.995M -89.298M -111.566M -166.014M -174.523M -60.011M
Free cash flow -93.828M -81.599M -76.887M -109.009M -132.346M -30.811M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 5.5 1.73 1.77 2.26 11.65 26.54
Price performance 12m 2.18 -0.02 -0.22 -0.81 -0.56 —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — 37.2M 38M 40.5M 43.9M 50.1M
Lease liabilities (USD) — — 23.1M 21.4M 19.6M 20M
Cash and deposits (USD) 251M 149M 87.9M 144M 139M 320M
Right-of-use assets (USD) — — 10.9M 9.58M 8.38M 9.44M
Net debt (borrowings + leases - cash) (USD) — -112M -26.8M -82.1M -75.5M -250M
Cash flow detail
Operating cash flow (USD) -30.7M -117M -88.4M -73M -81.2M -93.1M
Purchases of property, plant and equipment (USD) -82,000 -15.3M -20.6M -3.87M -374,000 -738,000
Change in payables (cash effect) (USD) 1.96M 14.5M -7.8M -2.3M -2.92M -153,000
Interest paid (cash effect) (USD) -28,000 -641,000 -2.78M -4.95M -5.28M -5.4M
Share-based compensation (USD) 3.35M 18.2M 18M 7.91M 13.1M 13.3M
Free cash flow (OCF - PPE - intangibles) (USD) -30.8M -132M -109M -76.9M -81.6M -93.8M
Income detail
Research and development expense (USD) 31.9M 132M 91.2M 56.8M 66M 86.4M
↳ 5y CAGR +22.1%
Total comprehensive income (USD) — — — -112M -93.3M -105M
Reported Mar 3, 2021 Mar 31, 2022 Mar 28, 2023 Feb 26, 2025 Feb 26, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027

TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL Phase 1/2, pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff

Completed BLA-enabling PPQ manufacturing campaign for TSHA-102, which met predefined product specifications as well as comparability criteria for commercial product and clinical material, supporting potential inclusion of REVEAL Part A Phase 1/2 data in the planned BLA

Encore data supporting TSHA-102 clinical program presented at the 55th Child Neurology Society Annual Meeting

Conference call and webcast today at 8:30 AM ET

Dallas – November 12, 2026 – Taysha Gene Therapies, Inc.

11-06-2026 |

PDF Version

DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on November 2, 2026, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, restricted stock units (RSUs) representing 25,000 shares of the Company’s common stock in connection with their employment. The RSUs were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest in four equal annual installments beginning on the first anniversary of the award's vesting commencement date, subject to such employee's continued service with the Company through each such vesting date.

About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact: [email protected]

Media Contact: [email protected]

Corporate Headquarters 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247

Laboratory Facility Morrisville, NC 27560

Scroll to top

11-05-2026 |

PDF Version

DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2026, and host a corporate update conference call and webcast on Thursday, November 12, 2026, at 8:30 AM Eastern Time.

Participants may access the live webcast of the conference call from the Events and Presentations page of Taysha’s website at ir.tayshagtx.com. An archived replay of the webcast will be available on the Company’s website.

About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact: [email protected]

Media Contact: [email protected]

Corporate Headquarters 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247

Laboratory Facility Morrisville, NC 27560

Scroll to top

Prompts

Taysha Gene Therapies, Inc. (ticker TSHA), listed in United States.

ETFs Holding Taysha Gene Therapies, Inc.

ETF Weight in ETF Shares Market value As of
SEIS 0.19% 164,992 $ 1.124M Jun 30, 2026
ESSC 0.15% 9,374 $ 54.932K Jul 31, 2026
FSEG 0.15% 1,259 $ 8,573.79 Jun 30, 2026
VFMO 0.10% 322,641 $ 1.836M Aug 31, 2026
FESM 0.10% 810,815 $ 5.522M Jun 30, 2026
RESM 0.05% 278 $ 1,893.18 Jun 30, 2026
MSSM 0.01% 8,003 $ 45.537K Aug 31, 2026
DFAS 0.00% 205,723 $ 866.094K Nov 12, 2026
DFSU 0.00% 9,865 $ 41.532K Nov 12, 2026
DXUV 0.00% 19,712 $ 82.988K Nov 12, 2026
DCOR 0.00% 107,194 $ 451.287K Nov 12, 2026
DFUS 0.00% 49,230 $ 207.258K Nov 12, 2026
DFAC 0.00% 115,015 $ 484.213K Nov 12, 2026
DFAU 0.00% 3,045 $ 12.819K Nov 12, 2026